FDA Panel Delivers Mixed Verdict on KAMRA Corneal Inlay

The FDA's Ophthalmic Devices Advisory Committee wrestled with flawed trial data that suggested efficacy but yielded some safety concerns, leading to overall uncertainty about benefit versus risk.
Medscape Medical News

Full Story →